The company's momentum has also elevated St. Louis' profile as a regional hub for the public and private sector advancement of high performance and cloud computing capabilities for genomics and other data intensive industries.
"It is great to see that Appistry is applying their extensive expertise in manipulating large data systems to work with the massive databases generated by sequencing whole genome," said Marcia Mellitz, vice president, Program Development, BioSTL. "St. Louis is an ideal location for the company given the presence of so many organizations advancing genetics research such as The Genome Institute at Washington University, University of Missouri, Monsanto and the Danforth Center."
Appistry continues to bolster its industry leading capabilities through the development of new pipelines for genomic research, including advanced RNA-Seq solutions for the rapid analysis of sequencing data. In the fall of 2011, Appistry officially launched a dedicated life sciences group to develop and commercialize technologies to transform unstructured next generation sequencing data into medically actionable intelligence. Appistry was frequently cited as a leading provider of genomic data analysis solutions in 2011 and continues to anticipate substantial growth in this market in 2012.
Appistry's new office is located in a 52,000-square-foot contemporary building well--suited for Appistry's recent expansion and future growth plans. In 2011 the company nearly doubled in size--reaching 50 employees. Appistry plans to continue aggressively identifying and hiring the world's most talented and experienced engineering and computer science professionals, such as Harlee Sorkin, the former Director of the Bio Entrepreneur Development Program at the Center for Emerging Technologies in St. Louis, who was recently hired to spearhead the company's business development efforts.
"2011 was a crucial year for Appistry as we successfully positioned ourselves to achieve significant growth in the life sciences market through product development and employee acquisition," said Kevin Haar, CEO of Appistry. "It is quite clear to us that the life sciences market continues to invest significantly in the genomics, translational and personalized medicine spaces. In 2012 and beyond, we are committed to harnessing this industry's growth by developing the most cost-effective, accurate and highest quality solutions for genomic analysis to accelerate a more personalized approach to medicine.